Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis
Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...
Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...
In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients
In a study published in Blood Advances, investigators reviewed data from a large cohort of patients who had undergone a hematopoietic cell transplantation (HCT)...
Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma
Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...
Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs
Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...
Lower Risk of GVHD With Parous Female Sibling Donors Than With Male Unrelated Donors
Donor’s sex and number of previous pregnancies are well established risk factors for graft-versus-host disease (GVHD) in hematopoietic cell transplantation (HCT), with male sibling...
Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions
In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...
DOACs Versus Warfarin in Patients With Cancer and Atrial Fibrillation
Newer direct oral anticoagulants (DOACs) offer an effective alternative to warfarin that does not require monitoring, but these agents are often not recommended in...
Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia
In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
